J
Jeffrey K Aronson
Researcher at University of Oxford
Publications - 615
Citations - 20721
Jeffrey K Aronson is an academic researcher from University of Oxford. The author has contributed to research in topics: Medicine & Computer science. The author has an hindex of 55, co-authored 523 publications receiving 17323 citations. Previous affiliations of Jeffrey K Aronson include British Pharmacological Society & National Institute for Health Research.
Papers
More filters
Journal ArticleDOI
Key concepts for making informed choices
Jeffrey K Aronson,Eric Barends,Robert Boruch,Marnie L. Brennan,Iain Chalmers,Joe Chislett,Peter Cunliffe-Jones,Astrid Dahlgren,Marie Gaarder,Andy Haines,Carl Heneghan,Robert T. Matthews,Brandy R. Maynard,Andrew D Oxman,Matt Oxman,Andrew S. Pullin,Nicola Randall,Hazel Roddam,Anel Schoonees,Jonathan M Sharples,Ruth Stewart,Janet Stott,Raymond Tallis,Nerys Thomas,Luke Vale +24 more
TL;DR: Teach people to think critically about claims and comparisons using these concepts and they will make better decisions, say Andrew D. Oxman and an alliance of 24 researchers.
Journal ArticleDOI
Global, regional, and national consumption of controlled opioids: a cross-sectional study of 214 countries and non-metropolitan territories:
TL;DR: Large disparities persist in most of the world in accessing essential opioid medicines, and collaborative strategies should be developed to promote access and the appropriate prescribing of opioids in all countries and non-metropolitan territories.
Journal ArticleDOI
The use of mechanistic evidence in drug approval
TL;DR: It is argued that mechanistic evidence is central to all the key tasks in the drug approval process: in drug discovery and development; assessing pharmaceutical quality; devising dosage regimens; assessing efficacy, harms, external validity, and cost‐effectiveness; evaluating adherence; and extending product licences.
Journal ArticleDOI
ABC of monitoring drug therapy. Phenytoin.
Journal ArticleDOI
Clinical Pharmacokinetics of Cardiac Glycosides in Patients with Renal Dysfunction
TL;DR: The pharmacokinetics of different cardiac glycosides are altered by renal dysfunction in different ways, depending on their basic pharmacokinetic properties, and changes seem to contribute little of clinical importance.